Metabolism & Obesity Service, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia; Boden Initiative, Charles Perkins Centre, Faculty of Medicine and Health, University of Sydney, NSW 2006, Australia.
University of Melbourne, Parkville, VIC 3010, Australia.
Obes Res Clin Pract. 2022 Sep-Oct;16(5):353-363. doi: 10.1016/j.orcp.2022.08.003. Epub 2022 Aug 30.
Obesity is a complex and multifactorial chronic disease with genetic, environmental, physiological and behavioural determinants that requires long-term care. Obesity is associated with a broad range of complications including type 2 diabetes, cardiovascular disease, dyslipidaemia, metabolic associated fatty liver disease, reproductive hormonal abnormalities, sleep apnoea, depression, osteoarthritis and certain cancers. An algorithm has been developed (with PubMed and Medline searched for all relevant articles from 1 Jan 2000-1 Oct 2021) to (i) assist primary care physicians in treatment decisions for non-pregnant adults with obesity, and (ii) provide a practical clinical tool to guide the implementation of existing guidelines (summarised in Appendix 1) for the treatment of obesity in the Australian primary care setting. MAIN RECOMMENDATIONS AND CHANGES IN MANAGEMENT: Treatment pathways should be determined by a person's anthropometry (body mass index (BMI) and waist circumference (WC)) and the presence and severity of obesity-related complications. A target of 10-15% weight loss is recommended for people with BMI 30-40 kg/m or abdominal obesity (WC > 88 cm in females, WC > 102 cm in males) without complications. The treatment focus should be supervised lifestyle interventions that may include a reduced or low energy diet, very low energy diet (VLED) or pharmacotherapy. For people with BMI 30-40 kg/m or abdominal obesity and complications, or those with BMI > 40 kg/m a weight loss target of 10-15% body weight is recommended, and management should include intensive interventions such as VLED, pharmacotherapy or bariatric surgery, which may be required in combination. A weight loss target of > 15% is recommended for those with BMI > 40 kg/m and complications and they should be referred to specialist care. Their treatment should include a VLED with or without pharmacotherapy and bariatric surgery.
肥胖是一种复杂的多因素慢性疾病,其发病与遗传、环境、生理和行为因素有关,需要长期治疗。肥胖与多种并发症相关,包括 2 型糖尿病、心血管疾病、血脂异常、代谢相关脂肪性肝病、生殖激素异常、睡眠呼吸暂停、抑郁、骨关节炎和某些癌症。已经制定了一个算法(在 PubMed 和 Medline 中搜索了 2000 年 1 月 1 日至 2021 年 10 月 1 日的所有相关文章),以(i)帮助初级保健医生做出肥胖非妊娠成年人的治疗决策,以及(ii)提供一个实用的临床工具,以指导澳大利亚初级保健环境中肥胖治疗现有指南(附录 1 中总结)的实施。主要推荐意见和管理变更:治疗途径应由一个人的人体测量学(体重指数(BMI)和腰围(WC))以及肥胖相关并发症的存在和严重程度决定。建议 BMI 为 30-40kg/m2 或腹部肥胖(女性 WC > 88cm,男性 WC > 102cm)且无并发症的患者体重减轻 10-15%。治疗重点应为监督生活方式干预,可能包括减少或低能量饮食、极低能量饮食(VLED)或药物治疗。对于 BMI 为 30-40kg/m2 或腹部肥胖和并发症的患者,或 BMI > 40kg/m2 的患者,建议体重减轻 10-15%,管理应包括强化干预,如 VLED、药物治疗或减肥手术,可能需要联合使用。对于 BMI > 40kg/m2 且有并发症的患者,建议体重减轻> 15%,并应转至专科治疗。他们的治疗应包括 VLED 联合或不联合药物治疗和减肥手术。